New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 30, 2014
09:02 EDTRCPTReceptos initiated with a Buy at Nomura
Target $63.
News For RCPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 30, 2015
09:26 EDTRCPTOn The Fly: Pre-market Movers
Subscribe for More Information
June 26, 2015
10:14 EDTRCPTOptions with decreasing implied volatility
Subscribe for More Information
June 19, 2015
10:27 EDTRCPTReceptos CFO says company has not canceled any events, Bloomberg reports
Subscribe for More Information
10:27 EDTRCPTReceptos calls active amid renewed takeover speculation
Subscribe for More Information
10:11 EDTRCPTReceptos did not cancel any conferences, says Evercore ISI
Evercore ISI commented on speculation that Receptos canceled out of conference and said the company has not canceled out of any brokers conferences.
10:08 EDTRCPTReceptos jumps amid continued takeover speculation
Speculation of a takeover is again taking shares of Receptos (RCPT) higher. The biopharma company, which has been frequently mentioned as a buyout candidate in blogs and analyst notes, is rumored to have canceled all of its conference appearances. The conference cancelations are unconfirmed, however, and itís not even clear if the company had any scheduled appearances. Further, while KYTHERA (KYTH) was recently acquired after canceling an appearance at a conference, such moves by companies often do not mean acquisition talks are underway. Shares of Receptos are well of their highs but remain up $1.94 to $189.06 in early trading.
09:49 EDTRCPTRumor: Receptos active amid renewed takeover speculation
Subscribe for More Information
June 18, 2015
09:22 EDTRCPTTheStreet's Feuerstein responds to Leerink note on Receptos
Subscribe for More Information
07:36 EDTRCPTReceptos remains an attractive takeover candidate, says Leerink
Subscribe for More Information
June 17, 2015
11:19 EDTRCPTInsider sales runs counter to Receptos takeover speculation, TheStreet reports
Subscribe for More Information
11:14 EDTRCPTLilly Ventures Fund sells 220,000 Receptos shares
Subscribe for More Information
June 16, 2015
14:23 EDTRCPTReceptos price target raised to $348 at Wedbush on M&A potential
Wedbush analysts Liana Moussatos and Kelechi Chikere said they'd interpreted Receptos (RCPT) comments with its earnings report in May about its ability to commercialize ozanimod on its own as a message to potential buyers that their bids were too low. Following a recent report from Proactive Investors, which claimed that Receptos had turned down bids of $200 per share from AstraZeneca (AZN) and $280 per share from Teva (TEVA) and Gilead (GILD), the analysts said they have reconsidered their valuation assumptions, as they believe these bid values could be accurate. Wedbush raised its fair value estimate on Receptos to $348 from $211, citing a belief in increased industry interest in ozanimod and the rest of Receptosí pipeline, and maintains an Outperform rating on the stock.
14:06 EDTRCPTReceptos price target raised to $348 from $211 at Wedbush
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use